Qsymia is approved for pediatric patients of what minimum age and BMI?

Qsymia, a combination medication used for weight management, is specifically approved for pediatric patients aged 12 years and older with a body mass index (BMI) at or above the 95th percentile for age and sex. The 95th percentile is a standard classification indicating that a child's weight is greater than or equal to 95% of children of the same age and sex, making it a critical threshold for identifying obesity in a pediatric population.

This age and BMI threshold is established based on clinical studies that demonstrated the medication's safety and efficacy in managing obesity in this demographic. The choice of 12 years and above reflects a consideration of the physiological and developmental stages in which treatment options may be appropriate and effective.